EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Triazolothiadiazine derivative positively modulates CXCR4 signaling and improves diabetic wound healing

Satyamaheshwar Peddibhotla, Karly Caples, Alka Mehta, Qi-Yin Chen, Junyi Hu, Shaquia Idlett-Ali, Liping Zhang, Carlos Zgheib, Junwang Xu, Kenneth W Liechty, Siobhan Malany

Biochemical Pharmacology · 2023

DOI: 10.1016/j.bcp.2023.115764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von Satyamaheshwar Peddibhotla und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Receptors, CXCR4, Wound Healing. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NIGMS NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Development of specific therapies that target and accelerate diabetic wound repair is an urgent need to alleviate pain and suffering and the huge socioeconomic burden of this debilitating disease. C-X-C Motif Chemokine Ligand 12 (CXCL12) also know an stromal cell-derived factor 1α (SDF-1α) is a chemokine that binds the CXC chemokine receptor type 4 (CXCR4) and activates downstream signaling resulting in recruitment of hematopoietic cells to locations of tissue injury and promotes tissue repair. In diabetes, low expression of CXCL12 correlates with impaired wound healing. Activation of CXCR4 receptor signaling with agonists or positive allosteric modulators (PAMs) provides a potential for small molecule therapeutic discovery and development. We recently reported high throughput screening and identification of the CXCR4 partial agonist UCUF-728, characterization of in vitro activity and reduced wound closure time in diabetic mice at 100 μM as a proof-of-concept study. We report here, the discovery of a second chemical scaffold demonstrating increased agonist potency and represented by thiadiazine derivative, UCUF-965. UCUF-965 is a potent partial agonist of β-arrestin recruitment in CXCR4 receptor overexpressing cell line. Furthermore, UCUF-965 potentiates the CXCL12 maximal response in cAMP signaling pathway, activates CXCL12 stimulated migration in lymphoblast cells and modulates the levels of specific microRNA involved in the complex wound repair process, specifically in mouse fibroblasts. Our results indicate that UCUF-965 acts as a PAM agonist of the CXCR4 receptor. Furthermore, UCUF-965 enhanced angiogenesis markers and reduced wound healing time by 36% at 10.0 μM in diabetic mice models compared to untreated control.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, ExperimentalReceptors, CXCR4Wound HealingAnimalsMiceCell MovementChemokine CXCL12Hematopoietic Stem CellsSignal Transduction

Stichwörter der Autor:innen

CXCR4 receptor agonistsDiabetic wound healingHigh-throughput screeningLymphoblast signalingPositive allosteric modulator agonistTriazolothiadizineUCUF965

Substanzen

Chemokine CXCL12Receptors, CXCR4

Autor:innen und Institutionen

  • Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
  • Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
  • Laboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver - Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO 80045, USA.
  • Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
  • Laboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver - Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO 80045, USA; Department of Physiology, University…
  • Laboratory for Fetal and Regenerative Biology, Department of Surgery, University of Colorado Denver - Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO 80045, USA. Electronic address: kliechty@arizona…

Förderung

  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • University of Colorado Anschutz Medical Campus

Zitieren

APA

Peddibhotla, S., Caples, K., Mehta, A., Chen, Q. Y., Hu, J., Idlett-Ali, S., Zhang, L., Zgheib, C., Xu, J., Liechty, K. W., & Malany, S. (2023). Triazolothiadiazine derivative positively modulates CXCR4 signaling and improves diabetic wound healing. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115764

Vancouver

Peddibhotla S, Caples K, Mehta A, Chen QY, Hu J, Idlett-Ali S, et al. Triazolothiadiazine derivative positively modulates CXCR4 signaling and improves diabetic wound healing. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115764

BibTeX
@article{Peddibhotla2023,
  author = {Peddibhotla, Satyamaheshwar and Caples, Karly and Mehta, Alka and Chen, Qi-Yin and Hu, Junyi and Idlett-Ali, Shaquia and Zhang, Liping and Zgheib, Carlos and Xu, Junwang and Liechty, Kenneth W and Malany, Siobhan},
  title = {Triazolothiadiazine derivative positively modulates CXCR4 signaling and improves diabetic wound healing},
  journal = {Biochemical Pharmacology},
  year = {2023},
  doi = {10.1016/j.bcp.2023.115764}
}
Kostenlos starten →